THE IMPACT OF MOUNJARO ON WEIGHT LOSS AND QUALITY OF LIFE

Authors

DOI:

https://doi.org/10.61164/jyvyyv93

Keywords:

Brazil; Quality of life; Obesity; Tizerpatide

Abstract

Obesity is one of the major public health challenges in Brazil, associated with several comorbidities. This study presents an integrative literature review on the impact of tirzepatide (Mounjaro) on weight loss and quality of life. The methodology included a systematic search in PubMed, Embase, Cochrane, SciELO, and Anvisa documents, from 2018 to 2025, using descriptors 'tirzepatide', 'obesity', 'quality of life', and 'SURMOUNT'. Randomized clinical trials, observational studies, and systematic reviews were included, while preclinical and case

reports were excluded. The analysis showed that tirzepatide leads to mean reductions of up to 22.8 kg at 72 weeks, surpassing semaglutide, in addition to improvements in metabolic and cardiovascular parameters. It also demonstrated positive impact on quality of life measures (EQ-5D, SF-36). It is concluded that tirzepatide is a promising therapy, provided it is integrated with public health policies and multidisciplinary care.

Downloads

Download data is not yet available.

References

CONSELHO REGIONAL DE MEDICINA DA PARAÍBA. Artigo | Tirzepatida: eficaz contra diabetes e obesidade. João Pessoa, 3 set. 2024. Acesso em: 29 set. 2025.

FERREIRA, Vanessa Alves; MAGALHÃES, Rosana. Obesidade no Brasil: tendências atuais. Revista Portuguesa de Saúde Pública, v. 24, n. 2, p. 71-81, 2006. Acesso em: 30 set. 2025

FREITAS, Túlio Martins; DE OLIVEIRA MOTA, Frederico Lucas; PINHEIRO, Abilail Paula. Terapias farmacológicas para tratar obesidade: análise de efeito e eficácia. Revista Foco, São Paulo, v. 17, n. 10, p. e6522-e6522, 2024. Acesso em: 29 set. 2025. DOI: https://doi.org/10.54751/revistafoco.v17n10-082

INTERDISCIPLINAR EM SAÚDE. O uso de tirzepatida no combate à obesidade: uma análise. 2024. Acesso em: 22 set. 2025.

LAGO, L. M. O uso da tirzepatida no tratamento da obesidade: revisão. Brazilian Journal of Interdisciplinary Health Sciences, [S.l.], 2025. Acesso em: 25 de set. 2025

OLHAR DA SAÚDE. Mounjaro® é aprovado pela Anvisa para tratamento da obesidade no Brasil. 9 jun. 2025. Acesso em: 05 de out. 2025.

SILVA, J. R.; LIMA, P. A.; ANDRADE, C. S. Avaliação do efeito da tirzepatida na perda de peso: revisão sistemática. Revista Brasileira de Obesidade, Nutrição e Emagrecimento, São Paulo, v. 19, n. 123, p. 45-56, 2025. Acesso em: 25 de set. 2025.

SINGH, Amit Kumar. The Science Behind Mounjaro and Wegovy for Weight Loss. [S.l.: s.n.], 2023. Acesso em: 22 de set. 2025.

Published

2025-11-19

How to Cite

THE IMPACT OF MOUNJARO ON WEIGHT LOSS AND QUALITY OF LIFE. (2025). Revista Multidisciplinar Do Nordeste Mineiro, 20(2), 1-10. https://doi.org/10.61164/jyvyyv93